Parabilis Medicines aims to raise 475 million in US IPO
The clinical-stage biopharmaceutical company plans to sell 25 million shares priced between 17 and 19 dollars each. Parabilis is developing a novel class of stabilized helical peptides and expects to list its stock on the Nasdaq under the ticker symbol PBLS.
Insights:
Parabilis Medicines plans to raise up to $475 million by offering 25 million shares priced between $17 and $19 in its initial public offering. This offering follows a string of well-received listings that have encouraged more clinical-stage biopharmaceutical firms to test public markets. The debut will signal whether investor appetite remains strong for novel drug-discovery platforms targeting historically difficult-to-treat diseases.
